In the circulation 25-hydroxyvitamin D (25(OH)D) is bound to vitamin D-binding protein (DBP) and albumin. Only a small fraction is in the unbound, free form. According to the ' free-hormone-hypothesis ' only the free form is biologically active. Genetic differences in DBP may affect the binding to 25(OH)D and thereby the amount of free 25(OH)D. In the present study sera were obtained from 265 postmenopausal women with low bone mass density (BMD). Serum 25(OH) D, DBP and albumin were measured and the free and bio-available (free ϩ albumin-bound) 25(OH)D calculated. Based on genotyping of the polymorphisms rs7041 and rs4588, the six common DBP phenotypes were identifi ed and the free and bio-available 25(OH)D calculated according to the corresponding binding coeffi cients. Relations between measures of 25(OH)D and PTH and BMD were evaluated with linear regression adjusted for age and BMI. The calculated amount of free and bio-available 25(OH)D was 0.03% and 13.1%, respectively, of the measured total serum 25(OH)D. Adjusting for DBP phenotype affected the calculated free and bio-available 25(OH)D levels up to 37.5%. All measures of 25(OH)D correlated signifi cantly with PTH, whereas a signifi cant association with BMD was only seen for the free and bio-available 25(OH)D measures. Adjusting for the DBP phenotypes improved the associations. These relations were almost exclusively seen in subjects not using vitamin D and/or calcium supplements. In conclusion, the free and bio-available forms of 25(OH) D may be a more informative measure of vitamin D status than total 25(OH)D. Adjustment for DBP phenotype may improve this further.
Introduction
Vitamin D is both a hormone and a vitamin. It can be obtained from the diet or produced endogenously from 7-dehydrocholesterol in the skin during UVB exposure. Vitamin D is hydroxylated in the liver to , the metabolite used to evaluate the vitamin D status. Further hydroxylation to 1, 25(OH) 2 D) , the active metabolite, takes place in the kidneys [1] 1,25(OH) 2 D increases calcium absorption in the intestines and reabsorption in the kidneys. It also increases calcium reabsorption in bone, and together with increased calcium levels, this inhibits parathyroid hormone (PTH) secretion from the parathyroid gland [4] . PTH increases osteoclast activity [5] . Thus, adequate vitamin D levels are important for bone health by ensuring suffi cient inhibition of PTH secretion. There is also evidence that vitamin D metabolites have multiple other biological effects like maintaining the immune system [6] , preventing cardiovascular disease [7] and diabetes [8] , and even decreased mortality [9] . In most [10 -12] but not all studies [13, 14] bone mass density (BMD) shows a positive correlation with vitamin D status. In the present study we wanted to test whether this association becomes stronger using the free and bio-available fraction of serum 25(OH) D as compared to the total serum levels of 25(OH) D. In addition, the impact of the free and bioavailable fraction of serum 25(OH)D on PTH levels were investigated.
DBP is a highly polymorphic protein with six major phenotypes, all with different binding affi nities for 25(OH)D [15] . These phenotypes are the results of two single nucleotide polymorphisms (SNPs) in the DBP gene (globulin-complex gene, GC gene), rs7041 and rs4588 [16] . We have therefore genotyped the subjects for these SNPs in order to apply the correct DBP binding coeffi cients for each individual in the calculations of free and bio-available 25(OH)D.
Materials and methods

Subjects
The blood samples were collected at baseline from post-menopausal women aged 50 -80 years old who participated in an osteoporosis intervention study [17] . Among the 297 subjects included in the osteoporosis study, 32 were missing data needed to calculate free 25(OH)D, leaving 265 subjects for the present analysis. The subjects were included from January 2007 until February 2009. All subjects had a T-score in total hip or lumbar spine Յ Ϫ 2. Exclusion criteria relevant to this study were suspected hyperparathyroidism (serum calcium Ͼ 2.55 mmol/L, serum calcium Ͼ 2.50 mmol/L combined with plasma PTH Ͼ 5.0 pmol/L, or serum calcium Ͼ 2.45 mmol/L combined with plasma PTH Ͼ 7.0 pmol/L). Further exclusion criteria were use of steroids, renal stone disease, systolic blood pressure Ͼ 175 mmHg or diastolic blood pressure Ͼ 105 mmHg, serum creatinine Ͼ 110 µ mol/L, chronic diseases like ischemic heart disease, diabetes, granulomatous disease, and cancer. No ethnic data were collected, but the large majority of the subjects were Caucasian and a few were Sami women.
Measurements
The subjects fi lled in a questionnaire on use of vitamin D and calcium supplements. Height and weight were measured with light clothing and no shoes. Total body, total hip, and lumbar spine (L1-L4) BMD were measured using dual X-ray absorptiometry (DEXA) (GE Lunar Prodigy, Lunar Corporation, Madison, WI, USA).
Serum was stored in aliquots at Ϫ 70 ° C for later analyses of total serum 25(OH)D and DBP. Serum 25(OH)D was measured at the Hormone Laboratory, Haukeland University Hospital, using an inhouse developed liquid chromatography double mass spectrometry method [18] . The reference range is 50 -113 nmol/L. The laboratory takes part in the external quality program DEQAS [19] . DBP was analyzed at the Hormone Laboratory, Aker University Hospital by an in house competitive radioimmunoassay according to Kauppinen-M ä kelin et al. [20] , reference range 3.0 -5.3 µ mol/L.
The other analyses were performed consecutively at the Department of Medical Biochemistry at the University Hospital of North Norway. Plasma PTH was measured using an automated clinical chemistry analyzer (Immulite 2000, Siemens Healthcare Diagnostics, Los Angeles, CA, USA), reference range 1.1 -7.5 pmol/L, and serum calcium was analyzed using an automated analyzer (Hitachi 917) with reagents from Boehringer Mannheim, reference range 2.15 -2.55 mmol/L. Albumin was measured by a colorimetric method (bromcresol green) using an automated analyzer, Cobas 800 (c702, Roche Diagnostics, Mannheim, Germany). The method was standardized to reference material BCR470/CRM470 from Institute for Reference Materials and Measurements (IRMM, Geel, Belgium). The reference interval was that elaborated jointly with The Nordic Reference Interval Project (NORIP), 18 - DNA was prepared from whole blood. Genotyping was performed by KBioscience (http://www. kbioscience.co.uk) using KBioscience Competitive Allele-Specifi c PCR genotyping system [21] .
Calculations of free and bio-available serum 25(OH)D
Calculations of free and albumin-bound 25(OH)D were done using a general formula developed by Vermeulen et al. [22] and tailored for calculating free 25(OH)D by Powe et al. [23] : 
Albumin-bound 25(OH
Bio-available 25(OH)D was calculated as the sum of free 25(OH)D and albumin-bound 25(OH) D. The binding coeffi cient used for albumin was 6 ϫ 10 5 and for DBP (without regard to DBP phenotype) 7 ϫ 10 8 [2] . In order to assign binding coeffi cients for the various DBP (or Gc) phenotypes, the subjects were genotyped for the two SNPs rs7041 and rs4588. For these two SNPs the following haplotypes are possible outcomes:
The GA-variant does not occur in humans on a regular basis, and therefore only the following diplotypes are relevant :   TA  TC  GC   TA  TA-TA  TA-TC  TA-GC  TC  TA-TC  TC-TC  GC-TC  GC  TA-GC  GC-TC  GC-GC Based on the binding coeffi cients for Gc-1S, Gc-1F and Gc-2 [15] , and the binding coeffi cient of combined haplotypes to be the mean of the two, the following binding coeffi cients for the specifi c DBP phenotypes were used in our calculations of ' SNP-adjusted ' free and bio-available 25 
Statistics
Normal distribution was evaluated by assessing histograms visually, and all variables were considered normally distributed.
Comparisons between groups were performed with Student ' s paired and unpaired t -tests. Linear regression was used to evaluate relations with adjustments for body mass index (BMI) and age. In this model the interaction between use of supplements (calcium and/or vitamin D) and measures of serum 25(OH)D and BMD appeared ( p ϭ 0.08). In this study, intake of cod liver oil was not included as a supplement as in Norway this most often is a life-long habit. Data are, where relevant, presented for subjects with and without supplements.
The statistical analyses were performed with SPSS. All tests were done two-tailed and a p -value Ͻ 0.05 was considered statistically signifi cant. The data are shown as mean (SD) unless otherwise specifi ed.
Ethics
The study was approved by the Regional Committee for Medical and Health Research Ethics (REK Nord).
Results
Twenty-fi ve subjects were taking calcium supplements alone, 18 subjects were taking vitamin D supplements alone, and 54 subjects were taking both calcium and vitamin D. In those taking calcium the mean supplement intake was 804 (268) mg/day, and in those taking vitamin D the mean supplement intake was 393 (247) IU/day. Although there appeared to be an interaction between use of supplements, measures of serum 25(OH)D and BMD, the distribution curves for 25(OH)D, DBP and albumin appeared similar in users and non-users of supplements ( Supplementary Figures 1 -15 , available online at http://informahealthcare.com/doi/abs/ 10.3109/00365513.2013.869701). One hundred and sixty-eight subjects had no supplements. The characteristics of the subjects are shown in Table I . As expected, serum calcium was signifi cantly higher, plasma PTH lower and measures of serum 25(OH) D higher in those on supplements. In the subjects not taking supplements the free and bio-available 25(OH)D were 0.03% and 13.1%, respectively, of the total serum 25(OH)D.
In those not using vitamin D supplements the mean serum 25(OH)D levels were non-signifi cantly higher in those included during the summer months (May -September) ( n ϭ 70) compared to those included during the winter months (October -April) ( n ϭ 123) (70.1 [17.7] vs. 65.0 [23.4] nmol/L, respectively), and similarly in those using vitamin D supplements 84.2 (15.7) ( n ϭ 31) and 80.5 (26.5) nmol/L ( n ϭ 41), respectively.
Using binding coeffi cients specifi c for the six DBP phenotypes ( ' SNP adjusting ' ) had a considerable effect on the estimated serum free and bio-available 25(OH)D levels. Thus, phenotype Gc-1S/Gc-2 ' SNP adjustment ' led to a calculated increase in free 25(OH) D of 37.5% and an increase in bio-available 25(OH) D of 26.8%. For the phenotype Gc-1F/Gc-1F a decrease of 34.7% and 34.6% for calculated free 25(OH)D and bio-available 25(OH)D, respectively, was found (Table II) . The serum DBP differed according to phenotype as expected [24] , with the Gc-2/ Gc-2 phenotype having the lowest and the GC-1 phenotypes the highest levels (Table II) .
In the linear regression model with BMI and age as covariates, almost all the 25(OH)D measures correlated signifi cantly and similarly with plasma PTH, in both users and non-users of supplements. There were no signifi cant relations with serum calcium and measures of serum 25(OH)D (data not shown). For BMD there were no signifi cant associations with total 25(OH)D. In subjects not using supplements, all measures of free and bio-available 25(OH)D had a signifi cant positive association with BMD total body. In this group, the ' SNP-adjusted ' free and bio-available 25(OH)D were also significantly and positively associated with BMD total hip (Table III) . Serum DBP was signifi cantly and negatively associated with BMD total body and BMD total hip (Table III) . No signifi cant relations were seen between serum albumin and BMD or PTH (Table III) .
Discussion
The main objective of this study was to examine whether free or bio-available 25(OH)D would correlate better with plasma PTH and BMD than total 25(OH)D; and secondly, to examine if using specifi c binding coeffi cients for the different DBP phenotypes in calculating the free and bio-available fraction of 25(OH)D would improve the results.
All measures of 25(OH)D had a strong and negative association with PTH. For BMD only the free and bio-available measures of 25(OH)D had a signifi cant positive association, whereas no significant associations were seen for total 25(OH)D. Although comparisons of standardized beta coefficients should be done with caution, it is noteworthy that at the hip the standardized beta-coeffi cients were fi ve times higher for free and bio-available 25(OH)D and BMD than what was observed for total 25(OH)D. It should be noted that these signifi cant associations were primarily seen in the subjects not using supplements. This is reasonable, as supplements will have a rapid effect on the serum 25(OH)D levels, whereas an effect on bone will come more slowly. In line with this, the high and almost equal relation between all measures of serum 25(OH)D and PTH refl ects the rapid response in PTH secretion to changes in vitamin D status, as that seen following vitamin D supplementation. 
DBP phenotypes
Gc-1S/Gc-1S
( n ϭ 73
Gc-1S/ Gc-1F ( n ϭ 59) specifi c assays, which at least for free 25(OH)D, hopefully will be available in the near future. And fi nally, the results were not completely consistent at all BMD measurement sites and need confi rmation in other studies.
On the other hand, we included a fairly large group of subjects and made adjustments and stratifi ed for relevant confounders. Also, adjusting the free and bio-available 25(OH)D levels for the different DBP binding coeffi cients is a novel and biologically logical approach.
The results of the study may have important clinical consequences. The free and/or bio-available fractions of 25(OH)D may be more strongly linked to important biological effects than the total fraction and may be benefi cial to assess for certain patient groups, such as postmenopausal females or others at risk of osteoporosis or low BMD. However, DBP is an expensive analysis. The increasing volume of 25(OH)D analyses being performed does not allow measurement and calculation of free and/or bioavailable 25(OH)D instead of total 25(OH)D for the general patient groups without a considerable cost. Genotyping of specifi c DBP phenotypes in order to more correctly calculate the free and/or bio-available 25(OH)D levels, would increase the costs of analysis even further.
In conclusion, our results indicate that free and bio-available 25(OH)D may be a more informative measure of the vitamin D status in relation to BMD, and also that adjusting for DBP phenotype may be a further improvement. However, the fi ndings need confi rmation in larger studies.
